The three new patents add to the company's existing portfolio and extend protection of the company's proprietary transdermal technology through at least 2028. Agile has also received a notice of allowance from the USPTO for the trademark Twirla(TM), and conditional acceptance from the FDA to use the proprietary name "Twirla" for its AG200-15 contraceptive patch, pending final agency review prior to NDA approval.
"We are thrilled that the USPTO issued these additional patents -- it underscores the proprietary nature of our transdermal technology and enhances the value of our intellectual property estate," said Al Altomari, President and CEO of Agile Therapeutics. "We are continuing to develop our patent portfolio in key markets around the world and the expansion in the U.S. is a great step forward."
Agile Therapeutics announces three new U.S. patents on its technology and the brand name Twirla(TM) for its first contraceptive patch
Agile Therapeutics today announced that the U.S. Patent and Trademark Office (USPTO) has issued three new patents with claims related to its contraceptive patch technology.
Aug 31, 2012
Companies in this press-release
Recommended
Recommended
Recommended
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Break out of the ordinary: see what’s new in life sciences packaging
At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.
REGISTER NOW & SAVE!
